RELMADA THERAPEUTICS INC

Company Overview

Relmada Therapeutics is a clinical‑stage biotechnology company focused on CNS and oncology small molecules and reformulations; it has no approved products or revenue and had a ~ $80M net loss in 2024 with an accumulated deficit of ~$640.9M. After a December 2024 futility readout for esmethadone (REL‑1017) the company pivoted from early‑stage internal programs to acquiring/in‑licensing mid‑ to late‑stage assets (notably Sepranolone acquired Feb 2025 and NDV‑101 in‑licensed Mar 2025). The current model emphasizes assets with clear commercialization pathways and limited sales‑force needs, lean internal headcount (17 employees at year‑end 2024), and reliance on partner milestones, royalties and milestone‑linked payments to fund development.

Executive Compensation Practices

Compensation will likely be highly equity‑centric given the company’s lack of revenue and constrained cash runway; management already reduced stock‑based compensation by ~$12.3M in 2024 due to aging vested grants and equity plan limits. Pay packages for executives are expected to emphasize milestone and deal‑linked incentives (e.g., payments tied to IND filings, Phase 2 readouts, licensing milestones and potential NDA events) and longer‑dated equity (options/RSUs) to align with binary clinical outcomes. Because Relmada is pursuing in‑licensing and acquisitions, acquisition/transaction bonuses, change‑of‑control protections and earnouts are likely components, while base salaries may be modest relative to larger biopharma; recent cost control and potential future financings will also pressure the use of equity over cash for retention.

Insider Trading Considerations

As a small, low‑revenue biotech with a concentrated cap table and recent share issuance (3,017,420 shares issued as part of the NDV‑101 license, ~10% of outstanding), insider transactions can have outsized market impact and signal confidence (or liquidity needs). Material events that routinely restrict trading and trigger Form 4 disclosure include clinical readouts (NDV‑101 Phase 2a/9‑ and 12‑month data), IND/NDA milestones, financing announcements and licensing deals; management has repeatedly flagged going‑concern risks, so financings are a likely catalyst for insider activity. Regulatory specifics (FDA/DEA scheduling for psychedelics and opioids, REMS requirements) heighten the materiality of clinical and regulatory updates, so expect tight blackout windows around data releases and higher likelihood of pre‑planned 10b5‑1 trading programs or lock‑ups following transactions.